Eastern Asia: Medicaments Containing Hormones Market 2024

Medicaments Containing Hormones Market Size in Eastern Asia

The East Asian medicaments containing hormones market rose notably to $X in 2022, picking up by X% against the previous year. In general, consumption showed prominent growth. Over the period under review, the market hit record highs at $X in 2020; however, from 2021 to 2022, consumption failed to regain momentum.

Medicaments Containing Hormones Production in Eastern Asia

In value terms, medicaments containing hormones production rose rapidly to $X in 2022 estimated in export price. Over the period under review, production continues to indicate a resilient expansion. The growth pace was the most rapid in 2019 when the production volume increased by X% against the previous year. The level of production peaked at $X in 2020; however, from 2021 to 2022, production stood at a somewhat lower figure.

Medicaments Containing Hormones Exports

Exports in Eastern Asia

Medicaments containing hormones exports declined remarkably to X tons in 2022, with a decrease of X% on 2021. Over the period under review, exports showed a abrupt contraction. The pace of growth was the most pronounced in 2014 with an increase of X%. The volume of export peaked at X tons in 2016; however, from 2017 to 2022, the exports stood at a somewhat lower figure.

In value terms, medicaments containing hormones exports soared to $X in 2022. Overall, exports, however, recorded a buoyant expansion. The most prominent rate of growth was recorded in 2014 when exports increased by X%. Over the period under review, the exports hit record highs in 2022 and are expected to retain growth in the near future.

Exports by Country

Taiwan (Chinese) (X tons) and Japan (X tons) represented the major exporters of medicaments containing hormones but not antibiotics in 2022, finishing at near X% and X% of total exports, respectively. South Korea (X tons) took the next position in the ranking, distantly followed by Hong Kong SAR (X tons). All these countries together held approx. X% share of total exports.

From 2012 to 2022, the biggest increases were recorded for Taiwan (Chinese) (with a CAGR of X%), while shipments for the other leaders experienced a decline in the exports figures.

In value terms, Japan ($X) remains the largest medicaments containing hormones supplier in Eastern Asia, comprising X% of total exports. The second position in the ranking was held by Taiwan (Chinese) ($X), with a X% share of total exports. It was followed by South Korea, with a X% share.

From 2012 to 2022, the average annual rate of growth in terms of value in Japan amounted to X%. In the other countries, the average annual rates were as follows: Taiwan (Chinese) (X% per year) and South Korea (X% per year).

Export Prices by Country

The export price in Eastern Asia stood at $X per ton in 2022, growing by X% against the previous year. In general, the export price recorded significant growth. As a result, the export price attained the peak level and is likely to continue growth in the immediate term.

There were significant differences in the average prices amongst the major exporting countries. In 2022, amid the top suppliers, the country with the highest price was Japan ($X per ton), while Taiwan (Chinese) ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by Japan (X%), while the other leaders experienced mixed trends in the export price figures.

Medicaments Containing Hormones Imports

Imports in Eastern Asia

After four years of decline, supplies from abroad of medicaments containing hormones but not antibiotics increased by X% to X tons in 2022. Over the period under review, imports, however, continue to indicate a abrupt slump. The pace of growth was the most pronounced in 2014 with an increase of X%. The volume of import peaked at X tons in 2012; however, from 2013 to 2022, imports remained at a lower figure.

In value terms, medicaments containing hormones imports expanded sharply to $X in 2022. In general, imports, however, showed a abrupt curtailment. The most prominent rate of growth was recorded in 2017 when imports increased by X% against the previous year. Over the period under review, imports attained the maximum at $X in 2012; however, from 2013 to 2022, imports failed to regain momentum.

Imports by Country

Japan prevails in imports structure, finishing at X tons, which was approx. X% of total imports in 2022. It was distantly followed by South Korea (X tons), creating a X% share of total imports. Hong Kong SAR (X tons) followed a long way behind the leaders.

Imports into Japan decreased at an average annual rate of X% from 2012 to 2022. Hong Kong SAR (X%) and South Korea (X%) illustrated a downward trend over the same period. While the share of Japan (X p.p.) increased significantly, the shares of the other countries remained relatively stable throughout the analyzed period.

In value terms, Japan ($X) constitutes the largest market for imported medicaments containing hormones but not antibiotics in Eastern Asia, comprising X% of total imports. The second position in the ranking was held by South Korea ($X), with an X% share of total imports.

From 2012 to 2022, the average annual growth rate of value in Japan amounted to X%. In the other countries, the average annual rates were as follows: South Korea (X% per year) and Hong Kong SAR (X% per year).

Import Prices by Country

In 2022, the import price in Eastern Asia amounted to $X per ton, with a decrease of X% against the previous year. Overall, the import price recorded a perceptible contraction. The pace of growth was the most pronounced in 2017 an increase of X% against the previous year. Over the period under review, import prices reached the maximum at $X per ton in 2012; however, from 2013 to 2022, import prices stood at a somewhat lower figure.

Prices varied noticeably by country of destination: amid the top importers, the country with the highest price was Hong Kong SAR ($X per ton), while Japan ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by Hong Kong SAR (X%), while the other leaders experienced a decline in the import price figures.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :